Alimemazine hemitartrate

Alimemazine hemitartrate (Trimeprazine hemitartrate) is an antagonist of the histamine (HA) receptor that can be taken orally and also acts as a partial agonist at other GPCR receptors. Alimemazine hemitartrate has effects that include anti-serotonin, antispasmodic, antihistamine, sedation, hypnotic, antiviral, and anti-nausea properties. Alimemazine hemitartrate promotes the growth of pancreatic β-cells in mice and improves diabetes in mice^[1][2][3]. IC50 & Target:HA receptor^[1] In Vitro:Alimemazine hemitartrate (20 μg/mL, 24 h) promotes CREB phosphorylation and increases the concentration of insulin receptor substrate 2 (IRS2)^[2].
Alimemazine hemitartrate (20 mg/L) antagonizes GPCR by inhibiting homologous agonists^[2].
Alimemazine hemitartrate (10 μM, 90 min) reduces the formation of syncytia induced by SARS-CoV-2 and its variants^[3].
Alimemazine hemitartrate (10 μM, 90 min) inhibits SARS-CoV-2 in HEK293T/ACE2 and VeroE6/TMPRSS2 cells^[3]. In Vivo:Alimemazine hemitartrate (10 mg/kg, intraperitoneal injection, once a day for 3 weeks) promotes mouse β-cell growth^[2].
Alimemazine hemitartrate (10 mg/kg, intraperitoneal injection, once a day for 22 days) synergistically reduces the progression of diabetes in NOD mice^[2].
Alimemazine hemitartrate (10 mg/kg, intraperitoneal injection, once a day for 7 days) promotes the proliferation and survival of β-cells in normal mice, but has little effect on β-cell defects caused by IRS2 deficiency^[2].
Alimemazine hemitartrate (10 mg/kg, oral gavage, two doses) does not reduce mouse lung virus titers^[3].